Patents Assigned to Precision Biologics, Inc.
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 8802090
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: August 12, 2014
    Assignee: Precision Biologics, Inc.
    Inventors: J. Andrew Bristol, Judith A Kantor
  • METHODS AND COMPOSITIONS RELATING TO COAGULATION ASSAYS
    Publication number: 20140038205
    Abstract: The invention provides methods and compositions relating to the detection and neutralization of heparin and heparin derivatives in vivo and in vitro. To neutralize heparin in a patient sample, a composition comprising a complex of a heparin-binding agent and a carrier compound is used prior to performing coagulation assays.
    Type: Application
    Filed: January 18, 2012
    Publication date: February 6, 2014
    Applicant: Precision BioLogic Inc.
    Inventor: Steven Jay Raynard
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 8535667
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: September 17, 2013
    Assignee: Precision Biologics, Inc.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang
  • Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
    Patent number: 8524456
    Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.
    Type: Grant
    Filed: August 19, 2010
    Date of Patent: September 3, 2013
    Assignee: Precision Biologics, Inc.
    Inventors: J. Andrew Bristol, Judith A. Kantor
  • COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES
    Publication number: 20130189268
    Abstract: This invention relates to NPC-1 antigen on the MUC5AC protein and 16C3 antigen on CEACAM5 and CEACAM6 proteins, and 31.1 epitope on the A33 protein are differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages. Further, NPC-1, 16C3, and/or 31.1 epitope specific antibodies and diagnostic and therapeutic methods of use.
    Type: Application
    Filed: June 22, 2011
    Publication date: July 25, 2013
    Applicant: Precision Biologics, Inc.
    Inventors: Xiulian Du, Janos Luka, Lewis Joe Stafford, Mark Semenuk, Xue-Ping Wang, Judith Kantor, Andrew J. Bristol